Objective: Lymph node metastasis is a characteristic of malignant cancers and is observed more frequently in oesophageal cancer than in other digestive tract cancers, making it one of the most important prognostic factors. Vascular endothelial growth factors C (VEGF-C) and D (VEGF-D) are important lymphangiogenic factors in human cancers and lymphangiogenesis is associated with lymph node metastasis. The aim of the study was to determine the correlation between pre-treatment serum levels of VEGF-C (sVEGF-C) and VEGF-D (sVEGF-D) and clinicopathologic features in patients with oesophageal cancer. Methods: Serum VEGF-C and sVEGF-D were measured by enzyme-linked immunoadsorbent assay (ELISA) on 149 patients with oesophageal cancer, 29 patients with benign oesophageal diseases and 30 healthy controls. Results: Serum VEGF-C and sVEGF-D levels were significantly higher in patients with oesophageal carcinoma than in the control group ( p < 0.001 and p = 0.001, respectively) or in the benign oesophageal diseases group ( p = 0.04 and p = 0.03, respectively). Subgroup analysis showed that lymph node metastasis ( p = 0.001), stage ( p = 0.001), tumour depth ( p = 0.006), resectability ( p = 0.002), tumour size ( p = 0.01), distant metastases ( p = 0.01) and histological grading ( p = 0.04) were correlated with an elevated level of sVEGF-C. Elevated levels of sVEGF-D were associated with tumour depth ( p = 0.002), stage ( p = 0.01) and lymph node metastasis ( p = 0.02). Among the patients (n = 83) who underwent potentially curative surgery, the overall survival time ( p = 0.008) was shorter for patients with a high level (>8667 pg ml À1 ) of sVEGF-C than for those with a low level (<8667 pg ml À1 ), when the cut-off value was determined on the basis of the median value in oesophageal cancer patients. On univariate regression analysis, tumour size, tumour depth, stage, lymph node metastases, distant metastases, resectability and sVEGF-C were found to be significant prognostic factors. Conclusions: These results suggest that pre-treatment levels of sVEGF-C and sVEGF-D reflect lymph node metastases and advanced stage of oesophageal cancer. Serum VEGF-C may be useful in predicting poor outcome for patients undergoing a potentially curative oesophagectomy. #
Introduction
Oesophageal cancer is one of the most lethal upper gastrointestinal malignancies in the world. It grows relatively fast [1] . Treatment outcomes of such patients have been poor because the disease has already progressed to an advanced stage by the time it is diagnosed. A special feature of oesophageal cancer is its early lymphatic spread into the regional lymph node. To date, no imaging modality has been proved to be consistently accurate in assessing lymph node metastasis in oesophageal cancer. Endoscopic ultrasonography (EUS), computed tomography (CT), 18F-fluoro-2-deoxyglucose positron emission tomography (FDG-PET) or integrated with CT (FDG-PET/CT), have been shown to be insufficiently accurate in assessing lymph node status in oesophageal cancer [2] . Various tumour markers have been used in attempts to detect oesophageal cancer and evaluated lymph nodes status; however, the sensitivities of these tumours markers are unacceptably low [3] . Nowadays, the extent of lymph node metastasis is the basis of all staging systems [4] . The presence of lymph node metastases that are occult or overlooked during surgery is a very important prognostic factor and greatly contributes to low survival rates. However, accurate preoperative prediction of lymph node involvement in oesophageal cancer is difficult and the gold standard remains histopathological examination of the resected nodes [5] .
Most cancers spread to distant sites primarily by means of lymphatic vessels, but the molecular mechanisms of tumour cell escape into lymphatic vessels and lymph node remain unclear [6, 7] . Vascular endothelial growth factors (VEGFs) and their receptors (VEGFRs) play an important role in the formation of the vascular network. Vascular endothelial growth factor C (VEGF-C) and D (VEGF-D) are relatively young members of the VEGF family, which are structurally closely related to each other and share approximately 30% identity with VEGF-A. They are considered to be a key regulator of lymphangiogenesis. Both stimulate the proliferation, migration and survival of endothelial cells in vitro. In addition, they have been shown to induce lymphangiogenesis and facilitate nodal metastases in transgenic mice and in other in vivo models [8, 9] .
VEGF-C and VEGF-D tumour overexpression is found in most cancers, where lymphatic involvement is observed [8, 10] . On the other hand, tumour VEGF-C and VEGF-D overexpression frequently correlates with the presence of regional nodal and distant metastases and, in some instances, with poor clinical outcomes [11, 12] . Serum VEGF-C and VEGF-D levels have been elevated, for example, in gastric, cervical and non-small cell lung cancer [13] [14] [15] .
In the current study, we measured the circulating VEGF-C and VEGF-D in the serum of patients with primary oesophageal cancer, and compared these levels in patients with benign oesophageal diseases as well as in healthy subjects. We correlated the concentration of examined VEGFs with clinicopathological findings. In addition, we defined the diagnostic sensitivity, specificity and areas under receiver operating characteristic (ROC) curves (referred to as AUCs) for the measurands and the potential clinical use of serum VEGF-C and VEGF-D as a biomarker of oesophageal cancer and diagnostic tool for determining lymph node metastasis.
Materials and methods

Patients
Serum samples were obtained from 178 individuals: 110 patients with histopathologically confirmed squamous cell carcinoma of the oesophagus, 39 with adenocarcioma of the lower part of the oesophagus or cardia and 29 patients with benign oesophageal diseases, treated in the Department of Thoracic Surgery of the Medical University of Bialystok. Clinicopathologic patient characteristics are listed in Table 1 . Among the cancer patients, there were 12 females and 137 males of median age 62 years (range: 36-83 years). The benign oesophageal disease group consisted of 12 patients with paraoesophageal hiatal hernia, three patients with leyomioma, three patients with Abricosow tumour and 11 patients with oesophageal diverticula. All primary tumour cases were staged clinically according to the guidelines of International Union Against Cancer tumour node metastasis (UICC TNM) [4] system on the basis of the upper digestive tract: contrast radiographic studies of the upper digestive tract with barium or gastrografin, endoscopy with biopsy and pathologic examination, EUS, posteroanterior and lateral chest radiography, ultrasound examination of the abdominal cavity and cervical nodes, thorax and an abdominal cavity CT, as also laparotomy and thoracotomy. Magnetic resonance imaging, bronchofibroscopy, endobronchial ultrasonographydirected fine-needle aspiration (EBUS-FNA) or bone scintigraphy were additionally performed if indicated. Only four patients had positron emission tomography (PET) scanning to detect distant metastasis. The diagnosis was confirmed each time by microscopic examination of the material obtained during biopsy and/or surgery. In the study, the following In most of the 66 cases, it was due to the advanced status of the disease, which was evidenced by the direct involvement of adjacent vital organs via local tumour extension (n = 11) or the presence of distant organ metastasis (n = 35); in others, it was due to poor performance status (n = 16); and in some, it was due to the patients' refusal to undergo the operation (n = 4). Of the 66 inoperable cases, 42 patients had undergone chemotherapy. Radiotherapy (52 gray) was administered to 10 patients. The stenting procedure was performed in four patients. Double stenting (oesophagus and trachea) was required in two patients. Six patients underwent feeding gastrostomy or jejunostomy and two patients refused further medication. After treatment, morbidity and mortality were documented. All the patients survived for at least 1 month after treatment and were followed up periodically, at intervals of 3-6 months, with clinical and laboratory examinations, including ultrasonography, computed tomography and chest radiography. The median follow-up period was 16 months (range: 1-91 months). A total of 106 of the patients died of cancer during the 8-year follow-up. No patients had received any blood transfusion or had undergone radiotherapy or chemotherapy prior to the start of the current study.
Control subjects
The control group consisted of 30 healthy volunteers (24 men and 6 women) without any chronic inflammatory conditions. The mean age of the controls at the time of sampling was 62.4 years. There were no significant differences in age or sex between the patients and controls.
Serum VEGF-C and VEGF-D analysis
Venous blood samples were drawn into sterile vacuum tubes when oesophageal carcinoma was detected before surgery or anticancer therapy. The tubes were centrifuged at 3000 rpm and separated sera were stored at À80 8C for future use. The values of VEGF-C and VEGF-D in the serum samples obtained were determined using the human VEGF-C enzyme immunoassay (EIA) kit (IBL-Hamburg, Germany) and the Quantiline human VEGF-D immunoassay kit (R&D System), respectively. Both commercially available enzyme-linked immunosorbent assay (ELISA) kits were used according to the manufacturer's recommendations. All specimens were assayed twice and the average of the two measurements was used in the data analysis. The limits of sensitivity of the VEGF-C and VEGF-D assays were 46.9 pg ml À1 and 31.3 pg ml À1 . The coefficient of variation was less than 5.0%.
Statistical analysis
Because the distributions of the lymphangiogenic factors showed no normal distribution (Shapiro-Wilk test: VEGF-C p < 0.001, VEGF-D p < 0.001), all studied groups were characterised by median values and as a range. The statistical differences regarding these variables in relation to several clinical and pathological parameters were assessed using the Mann-Whitney U-test for two groups and KruskalWallis one-way analysis of variance (ANOVA) for three or more groups. The overall survival was defined as the time from treatment initiation (surgical resection, chemotherapy or radiation) to the date of death from any cause or the last known follow-up examination. The Kaplan-Meier method was used to estimate the probability of overall survival as a function of time. The differences in the survival of subgroups of patients were compared by using Mantel's log-rank test. The prognostic value of VEGF-C and VEGF-D was examined in univariate analysis with the Cox hazard model. All p values were based on a two-tailed statistical analysis, and a p value less than 0.05 was considered significant. Moreover, we calculated the diagnostic criteria, such as diagnostic sensitivity, specificity and AUCs for the measurands. Statistical analyses were carried out using the Statistica 8.0 PL program (StatSoft Inc., Tulsa, OK, USA) and the GraphPad Prism 5.01 program (GraphPad Software, San Diego, CA, USA). The diagnostic criteria and ROC curves were calculated using the ROC analysis package included in the Statistica 8.0 PL program.
In accordance with the Declaration of Helsinki, the study protocol was approved by the local ethics committee and written informed consent was obtained from all participants before analysis.
Results
In oesophageal cancer patients, the median sVEGF-C and sVEGF-D levels were found to be statistically higher compared with healthy subjects (8667 vs 5007 pg ml À1 , p < 0.001 and 300.4 vs 159 pg ml À1 , p = 0.001, respectively) and with benign oesophageal diseases (8667 vs 7243 pg ml À1 , p = 0.04 and 300.4 vs 198.0 pg ml À1 , p = 0.03, respectively) ( Figs. 1 and 2) . The associations between the clinicopatho- Fig. 1 . Serum VEGF-C levels in patients with oesophageal cancer (n = 149), patients with benign oesophageal diseases (n = 29) and healthy control patients (n = 30). logical characteristics and the sVEGF-C and sVEGF-D levels in patients with oesophageal cancer are summarised in Table 2 . The level of sVEGF-C had no association with age, sex, location, histological type or residual tumour, but had a significant relationship with tumour size, histological grading, tumour depth, clinical stage, lymph node metastasis, distant metastasis and resectability. The sVEGF-D level was associated with tumour depth, the clinical stage and lymph node metastasis. However, there was no significant association between sVEGF-D and factors such as age, sex, location, tumour size, histological type, histological grade, distant metastasis, resectability or residual tumour.
Using ROC curves, sensitivity, specificity, positive and negative predictive values (PPV and NPV) were calculated for the presence of disease and for the detection of lymph node metastasis for each possible threshold value. The optimal cut-off values for application of the levels of sVEGF-C and sVEGF-D as markers of disease presence were 8003 pg ml
À1
and 278 pg ml À1 , respectively. The diagnostic values of sVEGF-C and sVEGF-D with respect to cancer detection were: sensitivity -60% and 52%, specificity -80% and 78%, PPV -86% and 82% and NPV -44% and 39%, respectively.
The optimal cut-off values for the application of levels of sVEGF-C and sVEGF-D as a detection of metastatic lymph node were 8422 pg ml À1 and 298 pg ml À1 , respectively. The diagnostic values of sVEGF-C and sVEGF-D as lymph node markers were: sensitivity -74% and 58%, specificity -61% and 50%, PPV -81% and 71% and NPV -51% and 39%, respectively.
The greater usefulness, based on AUCs, for differentiation between N1 and N0 patients was found for VEGF-C (VEGF-C À AUC = 0.704, VEGF-D À AUC = 0.577, p = 0.04) (Fig. 3) . The higher AUC was found for VEGF-C when compared with oesophageal cancer patients with distant metastasis in relation to those without distant metastasis (VEGF-C À AUC = 0.759, VEGF-D À AUC = 0.643, p = 0.048).
For assessing the prognostic value, we analysed patients with resected tumours. Patients with sVEGF-C levels less than the median level (8667 pg ml À1 ) were assigned to the lowlevel group (n = 48), whereas those with levels higher than the median were assigned to the high-level group (n = 35). The median overall survival of patients in the low-level group was 31 months (95% confidence interval (CI): 25-46) and patients in the high-level group was 20 months (95% CI: [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] ). The overall survival rates of patients with high pretreatment sVEGF-C levels were significantly lower than those of patients with low sVEGF-C levels ( p = 0.008) (Fig. 4) . The 3-year overall survival rate of patients with low sVEGF-C was 48.15% and that of patients with high sVEGF-C was 26.8%. No association between sVEGF-D levels (less and higher than median) and overall survival was found.
On univariate regression analysis, tumour size ( p = 0.002), tumour depth ( p < 0.001), stage ( p < 0.001), lymph node metastases ( p < 0.001), distant metastases ( p < 0.001), resectability ( p < 0.001) and sVEGF-C ( p = 0.001) were found to be significant prognostic factors. The sex ( p = 0.13), tumour location ( p = 0.89) and sVEGF-D concentration ( p = 0.08) did not significantly impact the outcome in this patient population (Table 3 ).
Discussion
Oesophageal cancer is one of the most lethal malignant tumours in the gastrointestinal carcinoma family. The rapid growth and invasive character of this tumour has often been associated with the systemic spread of the disease at diagnosis. Some of the conventional markers successfully applied for detecting other gastrointestinal tract cancers have been tested for their usefulness in primary diagnostics of oesophageal cancer patients, estimation of prognosis, the monitoring of therapy and early detection of tumour recurrence. However, the sensitivity and specificity of SCCantigen and carcinoembryonic antigen (CEA) -the tumour markers commonly used in the diagnosis of oesophageal cancer -were unsatisfactory [3] .
We observed a significant elevation of serum levels of VEGF-C and VEGF-D in our patient population in comparison with healthy people and those with benign oesophageal diseases. Our findings were in accordance with the findings of Krzystek-Korpacka et al. [16] , Kimura et al. [17] in oesophageal cancer and Wang et al. [18] in gastric cancer results, which showed that patients with cancer had significantly higher concentrations of sVEGF-C than healthy people. In a study of patients with lung cancer, Naumnik et al. [15] provided evidence that patients with advanced stages had higher sVEGF-D levels than healthy subjects. By contrast, Al-Moundhri et al. [19] showed that sVEGF-D levels were higher in the control group than in patients with gastric cancer. He suggested that the advanced tumour stage presentation in the cohort of patients may have led to the differential expression of the VEGF family members.
We found that the diagnostic values of serum VEGF-C and VEGF-D as disease markers were: sensitivity -60% and 52%; specificity -80% and 78%, respectively, values lower than those obtained by Krzystek-Korpacka et al. [16] , who calculated serum VEGF-C levels for application as a marker of disease presence to have a 70% sensitivity and a 81% specificity. However, the authors examined the serum concentration of VEGF-C in 70 patients with squamous cell carcinoma without adenocarcinoma of the lower oesophagus. To the best of our knowledge, this is the first report concerning sVEGF-D levels in oesophageal cancer.
Several investigations have shown that tumour expression of VEGF-C in squamous cell oesophageal cancer correlated with depth of tumour invasion, stage, lymphatic or venous invasion and the presence of lymph node metastasis [10, 20, 21] . We demonstrated that circulating VEGF-C depended strongly on the spread of cancer cells beyond the mucosae and the oesophagus. In our study, the levels of sVEGF-C in oesophageal cancer were increased in deeper invaded lesions, advanced stages and for those subjects with tumours larger than 4 cm. Our findings are in agreement with those obtained by Kimura et al. [20] and Matsumoto et al. [21] , who showed a significant correlation of VEGF-C tumour overexpression with the depth of tumour invasion and pathologic stage, as well as with the results of KrzystekKorpacka et al. [16] , who observed a tendency of serum VEGF-C elevation in advanced stages. Nauguchi et al. [22] reported that VEGF-C tumour overepression significantly correlates with the histological grade. In our investigation, we found a significant association between sVEGF-C levels and histopathologic grading.
We documented that sVEGF-C correlated significantly with the presence of metastases within lymph nodes and distant sites. In our study, the diagnostic value of circulating VEGF-C in respect to lymph node metastases was: sensitivity of 74% and specificity of 61%. The results of our study were in accordance with those of Krzystek-Korpacka et al. [16] for oesophageal cancer, Wang et al. [18] for gastric cancer, Tamura et al. [23] for the study of non-small cell lung cancer and Yu et al. [24] for thyroid carcinoma. Krzystek-Korpacka et al. [16] showed that the diagnostic value of sVEGF-C as lymph node metastasis was: sensitivity of 76% and specificity of 58%. In the studies on papillary thyroid carcinoma by Yu et al. [24] , sVEGF-C as a marker of lymph node involvement yielded similar results. Tamura et al. [23] revealed that the determination of sVEGF-C had higher sensitivity and specificity in diagnosing the presence of lymph node metastasis than that of a chest CT and might provide additional information to distinguish between the absence and presence of lymph node metastasis. However, no such correlation has been found in cervical cancers [14] . The correlation of sVEGF-C with the presence of nodal metastatic status of oesophageal cancer as shown in the present study may influence its role in facilitating the management of oesophageal cancer patients. In this study, patients with positive nodal status were those with ultrasonographic-and CT-detected nodal metastasis combined with a microscopic examination of lymph node in operated patients. The presence of clinically overt nodal metastases should be of more clinical relevance in indicating more aggressive tumour biology, but the assessment of lymph node involvement and presence of micrometastases in all anatomical regions in oesophageal cancers is difficult and conventional imaging techniques are regarded unsatisfactory [2] . The presence of lymph node metastases has an impact on the choice of treatment, resection extension, prognosis and the recurrence rate; therefore, our observation suggests the possible application of the sVEGF-C assay in the detection of lymph node metastasis in oesophageal cancer. In our study, patients with distant metastases had significantly higher serum levels of VEGF-C than patients without M1 disease. In this subgroup, most patients with distant metastases also had N1 disease. We also showed that non-resectable tumours had significantly higher concentrations of sVEGF-C than resectable tumours. Tzao et al. [12] showed that tumour expression of VEGF-D in squamous cell oesophageal cancer correlated with stage and N status. In our investigation, we found a significant association between serum concentration of VEGF-D and tumour depth, stage and lymph node metastasis. We did not find any correlation between serum levels of VEGF-D and age, sex, location, histological type, tumour size, histological grading, distant metastases, respectability and residual tumour.
In the present study, we also found higher usefulness of sVEGF-C levels than concentrations of sVEGF-D for differentiation between N1 and N0 as well as between M1 and M0 patients based on AUC. The sVEGF-C AUC was significantly higher than the sVEGF-D AUC in detecting lymph node metastases. We obtained similar results in detecting progression of oesophageal cancer to other organs. We found that sVEGF-C and sVEGF-D levels exhibited a significant correlation with clinicopathologic parameters of tumour progression, including the depth of tumour invasion, lymph node status and stage. In locally advanced oesophageal cancer, we applied neoadjuvant chemoradiation therapy to improve resectability and local control and adjuvant chemotherapy in the subgroup with node metastasis. Although judging resectability and selecting patients to combined modality therapy based on pre-treatment serum VEGF-C and VEGF-D levels is currently not practical (like other tumour markers), it may serve as an ancillary tool to predict the extent of the disease.
We observed a significant correlation between pretreatment serum levels of VEGF-C and the survival in resected patients. Patients with low serum VEGF-C in the peripheral vein had a significantly longer survival than patients with high serum concentration. No association between sVEGF-D levels in resected patients and overall survival was found.
In the present study, tumour size, tumour depth, stage, lymph node metastases, distant metastases, resectability and sVEGF-C level had prognostic significance in the univariate Cox regression analysis. However, in a multivariate analysis, serum VEGF-C level was not found to be a significant independent prognostic factor (data not shown). Okazawa et al. [25] showed a significant difference in survival between VEGF-C positive overexpression and negative overexpression groups of oesophageal cancer patients. In their study, multivariate analysis indicated that sex, age, VEGF-C expression and lymphatic invasion were prognostic determinants. Tzao et al. [12] demonstrated that positive tumour overexpression of VEGF-D was a strong independent survival predictor in resected squamous cell oesophageal cancer. Kimura et al. [17] revealed that high preoperative serum VEGF-C level significantly correlated with survival, and it was an independent risk factor for recurrence in resected oesophageal cancer. The same results were obtained by Wang et al. [18] for gastric cancer. Our data are consistent with these studies and we suggest that pretherapeutic circulating VEGF-C and VEGF-D levels might reflect the spread of cancer cells beyond the primary tumour and the formation of a metastatic focus through tumour-associated angiogenesis and lymphangiogenesis.
We conclude that pre-treatment serum levels of VEGF-C and VEGF-D reflect lymph node metastases and the advanced stage of oesophageal cancer. In locally advanced disease, serum VEGF-C concentrations may be useful in predicting poor overall survival in patients undergoing a potentially curative oesophagectomy and for assessment of the need for multimodality therapy. These findings might improve the therapeutic management of oesophageal cancer patients, although this issue requires further investigation.
